Plexxikon Inc.

Hoffmann-la Roche Inc.

Daiichi Sankyo Company, Limited

Osi Pharmaceuticals, Inc.

F. Hoffmann-la Roche Ag

Daiichi Sankyo, Inc.

Gary Conard Visor

Prabha N Ibrahim

Hamid Rezaei

Ralph Diodone

Tomoari Kamo

Hiroshi Yamakose

Navnit Hargovindas Shah

Dipen Desai

Harpreet Kaur Sandhu

Zenaida Go

Hans-Juergen Mair

Nicole Wyttenbach

Frank Wierschem

Raman Iyer

Stephan Lauper

Johannes Pudewell

Arlindo Lucas Castelhano

Marika Nespi

Urs Schwitter

Kristen Michelle Mulvihill

Shan-Ming Kuang

Baoshu Zhao

Karsten Fähnrich

Raman Mahadevan Iyer

Harpreet K Sandhu

Provided are solid dispersions of Compound I having the formula: wherein Compound I is substantially amorphous, methods of manufacturing said solid dispersions, and methods of using said solid dispersions.

Formulations of a compound modulating kinases

Provided are compositions comprising Compound I having the following structure: or a pharmaceutically acceptable salt thereof, and a solubilizing agent; methods of making the same; and methods of using the same.

Solid forms of the compound, [5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine HCl salt (Compound I) and its free base, active on the receptor protein kinases c-Kit and/or c-Fms and/or Flt3, were prepared and characterized:  Also provided are methods of using the solid forms.

Solid forms of a compound modulating kinases

Solid forms of Compound I (and its S-enantiomer, Compound II), active on protein kinases, were prepared and characterized: Also provided are methods of using the solid forms.

Solid forms of a compound for modulating kinases

Solid forms of the compound, [5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine HCl salt (Compound I) and its free base, active on the receptor protein kinases c-Kit and/or c-Fms and/or Flt3, were prepared and characterized: Also provided are methods of using the solid forms.

Provided are solid dispersions, solid molecular complexes, salts and crystalline polymorphs involving propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide.

Compositions and uses thereof

The present invention provides solid forms of the compound of formula 1 and pharmaceutical uses thereof. 

Solid forms of a pharmaceutically active substance

Salt forms of mTOR inhibitors of the Formula (I): and methods of preparation, formulation, and use in treating disease.

mTOR inhibitor salt forms

Growing community of inventors

Castro Valley, CA, United States of America

Gary Conard Visor